Foxo Technologies INC 8-K filings

FOXO Technologies' subsidiary, Vector BioSource, Inc., has entered into a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc., aiming to enhance its bio-product sourcing and expand its market reach.

FOXO Technologies Inc. announced its subsidiary, Vector BioSource, Inc., has entered into an asset purchase agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc.

FOXO Technologies Inc. CEO Seamus Lagan provided a mid-year update highlighting operational improvements, corporate restructuring, and strategic growth initiatives including potential acquisitions and a stock exchange uplisting.

FOXO Technologies Inc. announced the effectiveness of its 1-for-3,000 reverse stock split, aimed at increasing its per-share stock price for potential OTCQB quotation and future exchange uplisting.

FOXO Technologies has entered into an exclusive licensing agreement with founder Jon R. Sabes to commercialize its epigenetics intellectual property portfolio.

FOXO Technologies has reached a settlement with J.H. Darbie & Co. and received majority shareholder approval for a massive reverse stock split.

FOXO Technologies Inc. has exchanged Series A Preferred Stock for senior unsecured promissory notes with two institutional investors, totaling over $7.7 million.

FOXO Technologies Inc. has amended its Certificate of Incorporation to increase its total authorized capital stock to 25.02 billion shares.

FOXO Technologies Inc. has received majority stockholder approval to increase its authorized Class A Common Stock from 10 billion to 25 billion shares.

FOXO Technologies Inc. announced the resignation of its Chief Financial Officer, Sylwia Nowak Hauman, who cited concerns over internal controls, and the immediate appointment of Celene Laurene Rattray Grant as her successor.

FOXO Technologies Inc. has converted $200,000 in prior advances from related party Rennova Health, Inc. into 8,000 shares of Series E Preferred Stock.

FOXO Technologies Inc. increased its authorized common stock to 10 billion shares and announced its subsidiary, Big South Fork Medical Center, expanded clinical capabilities with new tele-specialty and cardiac diagnostic services.

FOXO Technologies Inc. has amended its Series B and C Preferred Stock conversion terms, significantly increased authorized common and preferred shares, and re-elected its board of directors.

FOXO Technologies Inc. CEO Seamus Lagan provided a year-end review highlighting significant operational growth, strategic acquisitions, and financial improvements in 2025.

FOXO Technologies Inc.'s behavioral health subsidiary, Myrtle Recovery Centers, received recognition from the Rural Health Association of Tennessee for its outstanding community impact.

FOXO Technologies Inc. filed amendments to its Certificate of Incorporation, revising conversion terms for Series D Preferred Stock and clarifying dividend frequency for Series E Preferred Stock.

FOXO Technologies Inc. has increased its authorized common stock from 500 million to 2.5 billion shares, effective October 22, 2025.

FOXO Technologies Inc. announced the appointment of Sylwia Nowak Hauman as its new CFO and filed an amendment to its Certificate of Incorporation regarding Series A Preferred Stock.

FOXO Technologies Inc. has finalized its acquisition of Vector Bio Source Inc., expanding its biotechnology and research services.

FOXO Technologies' majority stockholder approved a significant increase in authorized Class A Common Stock from 500 million to 2.5 billion shares.

FOXO Technologies Inc. has entered into a definitive agreement to acquire Vector BioSource Inc. for a combination of cash, preferred stock, warrants, and contingent preferred stock.

FOXO Technologies Inc. announced it has signed a stock purchase agreement to acquire Vector Biosource Inc., an information, data and biospecimen sourcing provider.

FOXO Technologies Inc. amended a settlement agreement to pay the remaining $97,837 balance in cash rather than issuing new shares.

FOXO Technologies' majority stockholder approved a reverse stock split with a ratio between 1:10 and 1:500, to be implemented by July 31, 2026.

FOXO Technologies Inc. faces delisting from NYSE American and announces restatement of its Q1 2025 financial statements due to an accounting error.

FOXO Technologies Inc. announced its Class A common stock will be delisted from NYSE American due to low selling price and will commence trading on the OTC market.

FOXO Technologies Inc. announced a non-binding agreement to acquire a South Florida assisted living facility for $22 million and expects to finalize the Vector Biosource acquisition soon.

FOXO Technologies Inc.'s behavioral health subsidiary, Myrtle Recovery Centers, Inc., has renewed its operating license for its Oneida, TN location and is at full capacity, prompting consideration of strategic expansion.

FOXO Technologies Inc. has implemented a 1-for-1.99 reverse stock split, effective July 27, 2025, with post-split trading commencing July 28, 2025.

FOXO Technologies Inc. announced its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary, focusing on its epigenetics business to unlock shareholder value and simplify business models.